Previous Page  8 / 9 Next Page
Information
Show Menu
Previous Page 8 / 9 Next Page
Page Background

Page 22

Note:

Cell and Gene Therapy 2018 & Clinical Microbiology Congress 2018

Biomedical Research

|

ISSN: 0976-1683

|

Volume 29

S e p t e m b e r 1 0 - 1 1 , 2 0 1 8 | D u b l i n , I r e l a n d

allied

academies

Joint Event on

CLINICAL AND MEDICAL MICROBIOLOGY

CELL AND GENE THERAPY

&

World Congress on

International Conference on

Ghada Mohammad Al-Ashmawy et al., Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C3-007

DOPAMINERGIC AGONISTS IMPROVE

OBESITY BY ITS ACTION ON LIPID

PROFILES AND LEPTIN

Ghada Mohammad Al-Ashmawy

1

, Eman Gouda Khedr

1

and

Abla Ebeed

2

1

Tanta University, Egypt

2

Delta University, Egypt

Background:

The efficacy of a non-prescription drug to support weight

loss programs has yet to be compared. This clinical trial investigates the

comparability of the lipase inhibitor orlistat and the dopaminergic agonist

bromocriptine.

Methods:

75 obese females were randomized into three groups according to

treatment received; obese control group (OC, n=25), orlistat group (OR, n=25,

120 mg capsules, three times a day) and bromocriptine group (OB, n=25, 20

mg tablet, once a day). This prospective observational study was conducted

with norm caloric diet for eight weeks. Serum concentration of leptin and lipid

profile were measured, along with Body Mass Index (BMI) at baseline and

after the study.

Results:

Bromocriptine treatment (OB) caused an increase in serum leptin

concentration compared to OC and OR groups (ANOVA, p<0.01). Beneficial

changes in anthropometric and BMI values were observed following orlistat

and bromocriptine administration with the greatest advantage seen in the OB

group.

Conclusions:

Beneficial effects were observed on weight loss, and body

composition in all examined groups, with the greatest advantage on serum

leptin being associated with the bromocriptine treatment. We find these

strategies more promising for the treatment of obesity and its related

complications in obese women.

Ghada Al-Ashmawy is currently working in Tanta

University, Egypt.

ghadaashmawy@pharm.tanta.edu.eg

BIOGRAPHY